Produced in partnership with IBTV, our Roving Reporter series captures real-time perspectives from across the life sciences industry. Filmed on the show floor at ASGCT 2026 in Boston, this episode brings together leading voices from across cell and gene therapy to explore which innovations are having the greatest impact on manufacturing scalability, consistency, and commercial readiness.
Manufacturing remains one of the biggest barriers to the widespread adoption of cell and gene therapies. Industry experts point to stable cell lines, process intensification, AI-driven process modeling, operational excellence, and quality-by-design as important tools for increasing output while maintaining product quality. Flexible manufacturing models and stronger analytical technologies could also help developers adapt production to different therapeutic modalities and patient populations.
Featuring insights from John Tomtishen of Catalent, Andrew Scheffler of ScaleReady, Emmanuelle Cameau of Cytiva, Jimmy Vanhove of Viralgen, Nick Randall of Repligen, Heather Purvis of Title21 Health Solutions, Bryan Deuber of Andelyn, David Radspinner of VintaBio, Natalia Elizalde of VIVEbiotech, Andrew Lewin of Lentitek, and Francesca Vidali of ReiThera, the discussion considers the importance of regulatory flexibility, data-led process control, and off-the-shelf therapies as the field moves closer to large-scale commercialization.
Watch the video below.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
